Questions About Cancer? 1-800-4-CANCER

Cannabis and Cannabinoids (PDQ®)

Health Professional Version
Last Modified: 05/13/2014

Changes to This Summary (05/13/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Laboratory/Animal/Preclinical Studies

Added text to state that a subsequent study found that the antiproliferative effect of cannabidiol was counteracted by selective CB1 but not CB2 receptor antagonists, suggesting an involvement of CB1 receptors (cited Romano et al. as reference 21).

This summary is written and maintained by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.